<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>Vaccination News</title>
      <link>http://vaccine.immunodefence.com/</link>
      <description>Immunization, new vaccines development to fight HIV/AIDS, Flu, Bird-flu, Cancer, Allergy and other diseases.Risks and effectiveness of vaccines.</description>
      <language>en</language>
      <copyright>Copyright 2008</copyright>
      <lastBuildDate>Sat, 16 Feb 2008 16:39:19 +0100</lastBuildDate>
      <generator>http://www.sixapart.com/movabletype/</generator>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs> 

            <item>
         <title>Deaths Associated with HPV Vaccine Start Rolling In, Over 3500 Adverse Affects Reported</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/01f1.gif" border="0" hspace="2" vspace="2" width="100" height="100" align="left" />TORONTO, September 20, 2007 (LifeSiteNews.com) - As Canada, in large part due to aggressive behind the scenes lobbying, rolls out the not-comprehensively-tested Merck HPV vaccine for girls as young as nine, a look at developments on the vaccine south of the border should cause Canadians serious concern.&nbsp; In the United States a similar lobby campaign by the same company launched the mass HPV vaccination of girls beginning in June last year. &nbsp;<br /><br />In just little over a year, the HPV vaccine has been associated with at least five deaths, not to mention thousands of reports of adverse effects, hundreds deemed serious, and many that required hospitalization.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2008/02/deaths_associated_with_hpv_vac.html</link>
         <guid>http://vaccine.immunodefence.com/2008/02/deaths_associated_with_hpv_vac.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">HPV</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">HPV cancer</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccination for children</category>
        
         <pubDate>Sat, 16 Feb 2008 16:39:19 +0100</pubDate>
      </item>
            <item>
         <title>Novartis inks $500M anti-smoking vaccine pact</title>
         <description><![CDATA[<p><img src="http://www.immunodefence.com/ii/smoke.jpg" border="1" hspace="2" vspace="2" width="120" height="134" align="left" />Novartis has demonstrated its commitment to the vaccine market with a $500 million (600 million Swiss francs) global licensing deal for Switzerland&#39;s Cytos Biotechnology&#39;s anti-smoking vaccine. Cytos gains 35 million Swiss francs up front for CYT002-NicQb, which is scheduled to go into late-stage trials in 2008. The rest of the money will be paid in scheduled milestones for a successful development program. Novartis takes over all development costs and responsibilities. NicQb works by spurring the development of antibodies that attach to nicotine molecules, making them too big to penetrate the blood-brain barrier, thereby reducing nicotine stimulation.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/04/novartis_inks_500m_antismoking.html</link>
         <guid>http://vaccine.immunodefence.com/2007/04/novartis_inks_500m_antismoking.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">General Vaccination News</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">anti-smoking vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">smoking</category>
        
         <pubDate>Wed, 25 Apr 2007 22:40:18 +0100</pubDate>
      </item>
            <item>
         <title>Senate votes to overturn Perry&apos;s vaccination order</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/senate.jpg" border="0" alt="senate" title="senate" hspace="4" vspace="2" width="107" height="100" align="left" />AUSTIN &mdash; The Senate Monday passed a bill overturning Gov. Rick Perry&#39;s order that middle-school girls be vaccinated against a sexually transmitted virus linked to cervical cancer, with a requirement that the issue be reviewed in four years.</p> <p>After a brief debate, the Senate voted 30-1, with Sen. Leticia Van de Putte, D-San Antonio, casting the lone &quot;no&quot; vote.</p> <p>The bill would prevent the HPV vaccine from being required for school enrollment until 2011. The version passed by the House has no expiration date.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/04/senate_votes_to_overturn_perry.html</link>
         <guid>http://vaccine.immunodefence.com/2007/04/senate_votes_to_overturn_perry.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">cervical cancer</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">HPV cancer</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">politics</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccine</category>
        
         <pubDate>Tue, 24 Apr 2007 15:31:05 +0100</pubDate>
      </item>
            <item>
         <title>Taking A Jab At Cancer By Stimulating The Immune System</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/clinical_trials1.jpg" border="0" alt="clinical trials" title="clinical trials" hspace="4" vspace="2" width="100" height="150" align="right" />As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress. While HPV vaccine efforts had the &quot;benefit&quot; of a viral source for the disease, other researchers are developing vaccines for cancers that are not virally based, in an effort to coax the immune system into attacking cancerous cells. </p><p>At the 2007 Annual Meeting of the American Association for Cancer Research, presentations on ongoing HPV trials and other new approaches to stimulating the immune system are injecting momentum into cancer vaccine research. </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/04/taking_a_jab_at_cancer_by_stim.html</link>
         <guid>http://vaccine.immunodefence.com/2007/04/taking_a_jab_at_cancer_by_stim.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">cancer vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">clinical trials</category>
        
         <pubDate>Tue, 24 Apr 2007 15:28:15 +0100</pubDate>
      </item>
            <item>
         <title>Italy to Offer Cervical Cancer Vaccine</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/01f1.gif" border="0" hspace="2" vspace="2" width="100" height="100" align="left" />A vaccine against the sexually transmitted virus that can cause cervical cancer went on sale Wednesday in Italy, the first European Union nation to offer the vaccine free for 12-year-old girls, the Italian Health Ministry said.<br /><br />The ministry said a campaign will be launched soon to encourage the free vaccination of 12-year-olds but that the vaccine for the human papillomavirus, of HPV, will not be mandatory. Older girls and women who want the vaccination will have to pay for it.</p><p>Proponents of the vaccine say it will be most effective when given before girls become sexually active. Ministry officials said the vaccine is being supplied by Sanofi-Pasteur, the vaccine division of Sanofi-Aventis. </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/italy_to_offer_cervical_cancer.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/italy_to_offer_cervical_cancer.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">cancer</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">HPV</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">human papillomavirus</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccine</category>
        
         <pubDate>Thu, 29 Mar 2007 00:42:17 +0100</pubDate>
      </item>
            <item>
         <title>Merck’s Miracle Vaccine –What Is This Story Really About?</title>
         <description><![CDATA[<em><img src="http://immunodefence.com/ii/merck_logo.jpg" border="0" alt="merck" title="merck" hspace="4" vspace="2" width="100" height="100" align="right" />By Maggie Mahar</em>, The Health Care Blog<p>February 22, 2007 - Yesterday, Merck announced that it is no longer going to try to persuade states  to make its new $360 cervical cancer vaccine mandatory for all pre-teens. (At  least, not publicly). The company wouldn&rsquo;t divulge how much it has spent, to  date, on its lobbying campaign.</p> <p>Virtually everyone has heard about &ldquo;Gardasil.&rdquo; Planned Parenthood backs it.  Women in Government extols its virtues. (Both organizations receive significant  contributions from Merck). Not long ago, a glowing New York Times editorial  congratulated Texas governor Rick Perry for mandating &ldquo;<a href="http://select.nytimes.com/search/restricted/article?res=F60615F9385B0C758CDDAB0894DF404482%29">A  Vaccine To&nbsp; Save Women&rsquo;s Lives</a>.&rdquo;( So far as I know, Merck makes no  contributions to The New York Times, but Perry&rsquo;s former chief of staff is a  Merck lobbyist.) At this point, twenty states have drafted plans to follow  Perry&rsquo;s example.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/mercks_miracle_vaccine_what_is.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/mercks_miracle_vaccine_what_is.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">cancer vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">gardasil</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">merck</category>
        
         <pubDate>Wed, 07 Mar 2007 12:33:22 +0100</pubDate>
      </item>
            <item>
         <title>Deaf girl sues over MMR vaccine</title>
         <description><![CDATA[<p align="left"><img src="http://immunodefence.com/ii/mmr_vaccine.jpg" border="0" alt="MMR vaccine" title="MMR vaccine" hspace="4" vspace="2" width="100" height="100" align="left" />A TEENAGER is fighting to prove that the MMR vaccine made her  deaf.</p>  <p align="left">Katie Stephen, 16, fell ill with a fever 10 days after being  injected with an early form of the immunisation as a toddler in 1991.</p>  <p align="left">Parents Wendy and Alistair believe the vaccine, which included a  strain of mumps, was responsible for their daughter losing the hearing in her  left ear.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/deaf_girl_sues_over_mmr_vaccin.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/deaf_girl_sues_over_mmr_vaccin.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Safety and Effectiveness</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">MMR vaccination</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">risk</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">side-effects</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccination for children</category>
        
         <pubDate>Wed, 07 Mar 2007 12:28:31 +0100</pubDate>
      </item>
            <item>
         <title>Nasal flu vaccine works better for kids</title>
         <description><![CDATA[<img src="http://www.immunodefence.com/ii/girl_flu.jpg" border="1" hspace="2" vspace="2" width="114" height="110" align="right" /><p>Children given a flu vaccine by nasal spray were better protected against the disease than those given the old shot in the arm, according to new research in the most recent New England Journal of Medicine.</p> <p>The study, which followed nearly 8,500 children in 16 countries, found the vaccine sniffed up the nose reduced the influenza &quot;attack rate&quot; in children by 55 percent compared to the traditional injections.</p><p>The attack rate is the number of people who get sick compared to the total number of people in a study group.</p><p>&quot;Children get the flu twice as often as adults,&quot; said Dr. Robert Belshe of St. Louis University, the study&#39;s lead author. &quot;It&#39;s important to vaccinate kids against influenza -- and to identify new and more effective flu vaccine options -- because kids have a higher attack rate for influenza infection than adults.&quot; </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/nasal_flu_vaccine_works_better.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/nasal_flu_vaccine_works_better.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Influenza</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">flu</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">influenza</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">nasal spray</category>
        
         <pubDate>Sun, 04 Mar 2007 00:49:58 +0100</pubDate>
      </item>
            <item>
         <title>New Powdered Tuberculosis Vaccine May Lead to Life-Saving Aerosol</title>
         <description><![CDATA[<p><img src="http://www.immunodefence.com/ii/tuberculosis.jpg" border="0" alt="Powdered Tuberculosis Vaccine" title="Powdered Tuberculosis Vaccine" hspace="2" vspace="2" width="143" height="100" align="left" /><strong>Early tests set the stage for health workers to administer the vaccine as an aerosol instead of an injection.</strong></p><p> 	 		<em>A new powdered form of BCG, the tuberculosis vaccine, mixes a mycobacterium [green] with leucine [</em><em>gray] and may pave the way for more powerful, needle-free forms of the vaccine. <br /></em></p><p>A new powdered form of tuberculosis (TB) vaccine may help save some of the nearly two million lives lost to the disease annually. In preliminary tests, the powdered form contained more active bacterial cells than a freeze-dried version similar to the existing vaccine. The result may pave the way for health workers to administer the vaccine as an aerosol to the lungs instead of as an injection, possibly leading to a more effective treatment. </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/new_powdered_tuberculosis_vacc.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/new_powdered_tuberculosis_vacc.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Tuberculosis Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">BCG</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">tuberculosis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccine trials</category>
        
         <pubDate>Sun, 04 Mar 2007 00:33:50 +0100</pubDate>
      </item>
            <item>
         <title>Cervical cancer vaccine users see side effects</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/gardasil_syringe.jpg" border="0" alt="gardasil" title="gardasil" hspace="4" vspace="2" width="158" height="100" align="right" />Genital warts. Cervical cancer. Vaginal disease. All these afflictions are caused by the human papillomavirus. Recently, women have had an opportunity to decrease their chances of contracting the virus as a result of the new three-dose vaccine from Merck &amp; Co. Inc. called Gardasil.</p><p>In recent news, however, the adequacy of the warning label provided by the Center for Disease Control has been tested by the public, as numerous complaints of side effects have surfaced after patients received their HPV vaccinations.</p><p>As of now, a report has stated that over 500 people have complained of post-vaccination side effects such as fainting and dizziness, and there have been three recorded cases of the Guillain-Barr&eacute; syndrome. According to health professionals, the syndrome is a rare disorder within the nervous system that sometimes causes complete paralysis. </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/cervical_cancer_vaccine_users.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/cervical_cancer_vaccine_users.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">gardasil</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">safety</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">side-effects</category>
        
         <pubDate>Thu, 01 Mar 2007 13:50:39 +0100</pubDate>
      </item>
            <item>
         <title>Hepatitis E Vaccine Shows Promise</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/clinical_trials1.jpg" border="0" alt="clinical trials" title="clinical trials" hspace="4" vspace="2" width="100" height="150" align="left" />Feb. 28, 2007 -- An experimental <span class="no_cross_link">hepatitis</span> E vaccine shows promise but needs further study, experts report in <em>The New England Journal of Medicine</em>.</p> <p>Hepatitis E is a liver disease caused by the hepatitis E virus, which spreads through contaminated food or water. </p> <p>Hepatitis E is rare in the U.S., but it&#39;s a major public health problem in developing countries. The disease is most dangerous for pregnant women, who can die or have miscarriages or stillbirths due to hepatitis E.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/03/hepatitis_e_vaccine_shows_prom.html</link>
         <guid>http://vaccine.immunodefence.com/2007/03/hepatitis_e_vaccine_shows_prom.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Hepatitis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">gsk</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">hepatitis e vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">study</category>
        
         <pubDate>Thu, 01 Mar 2007 13:45:35 +0100</pubDate>
      </item>
            <item>
         <title>ALK Abello presents positive results for Grazax pollen vaccine</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/alk_logo.jpg" border="0" alt="ALK Abello" title="ALK Abello" hspace="4" vspace="2" width="156" height="55" align="right" /> COPENHAGEN (AFX) - Danish pharmaceutical group ALK Abello AS said its tablet-based grass pollen vaccine Grazax showed very positive results for the second treatment year in the ongoing GRAZAX GT-08 study.</p><p> In the second treatment year, Grazax reduces hay fever symptoms by 44 pct and reduces the need for symptom-relieving medication by 73 pct compared with placebo, ALK Abello said.</p><p> ALK Abello said it has recently entered strategic alliances for the Grazax programme with the Menarini Group for some European markets and with <strong>Schering-Plough</strong>      (nyse:       <a href="http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?tkr=SGP">SGP</a> -  	<a href="http://www.forbes.com/markets/company_news.jhtml?ticker=SGP">        news     </a> -      <a href="http://www.forbes.com/peopletracker/results.jhtml?startRow=0&amp;name=&amp;ticker=SGP">        people     </a>) for North America..</p><p><em>Copyright AFX News</em></p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/02/alk_abello_presents_positive_r.html</link>
         <guid>http://vaccine.immunodefence.com/2007/02/alk_abello_presents_positive_r.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Allergy Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">alk-abello</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">allergy vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">grazax</category>
        
         <pubDate>Tue, 27 Feb 2007 14:39:47 +0100</pubDate>
      </item>
            <item>
         <title>PAKISTAN: Religious leaders fight vaccine propaganda</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/vaccine_shot.jpg" border="0" alt="vaccine shot" title="vaccine shot" hspace="4" vspace="2" width="120" height="148" align="left" />ISLAMABAD, 27 February 2007 (IRIN) - Muslim and community leaders are seeking to counter the disinformation surrounding polio vaccinations in parts of Pakistan&#39;s North West Frontier Province (NWFP) and tribal areas. </p><p>&quot;To make people understand the importance of polio immunisation in an Islamic context is extremely important. We are engaging moderate religious leaders, community leaders and influential tribal elders. And we are holding community jirgas [councils] to address the concerns of the parents and ensure their children are vaccinated,&quot; said Melissa Corkum, a spokesperson for the United Nations Children&#39;s Fund (UNICEF) in the Pakistani capital, Islamabad. </p><p>The message is &quot;that the polio vaccine is safe and that the same vaccine has been used to eradicate polio in other Muslim countries like Saudi Arabia and Indonesia&quot;, Corkum said.&nbsp; </p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/02/pakistan_religious_leaders_fig.html</link>
         <guid>http://vaccine.immunodefence.com/2007/02/pakistan_religious_leaders_fig.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">General Vaccination News</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">pakistan</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">polio</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">religion</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">WHO</category>
        
         <pubDate>Tue, 27 Feb 2007 14:37:24 +0100</pubDate>
      </item>
            <item>
         <title>Lovaxin helps cancer fight</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/advaxis_logo.jpg" border="0" alt="advaxis" title="advaxis" hspace="4" vspace="2" width="103" height="98" align="right" />Drug development company Advaxis, has created a family of vaccines, Lovaxin, which encourages the immune system to attack cancer in the same way it would a flu vaccine.</p><p>Dr. Vafa Shahabi, Advaxis&#39; Director of Research and Development, reports that because the human immune system is not designed to fight cancer on its own, she and her colleagues are trying to harness its power through a new kind of life form: specifically a family of vaccines, which they call Lovaxin. The vaccines are comprised of new strains of bacteria created in Advaxis&#39; laboratory that are programmed to kill off specific cancers.</p><p>Central to this startling discovery is the microbe Listeria monocytogenes, a common bacterium found in milk, cheese and other dairy products. This microorganism apparently aids in fighting cancer by activating the body&#39;s own killer (cytotoxic T) cells to elicit a stronger than normal immune response to the presence of cancer cells. The vaccines &quot;teach&quot; the immune system to mount a specialized, targeted response that is lethal to cancer.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/02/lovaxin_helps_cancer_fight.html</link>
         <guid>http://vaccine.immunodefence.com/2007/02/lovaxin_helps_cancer_fight.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Cancer Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">advaxis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">cancer vaccine</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">flu</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">lovaxin</category>
        
         <pubDate>Tue, 27 Feb 2007 14:34:34 +0100</pubDate>
      </item>
            <item>
         <title>Merck Updates Prescribing Information For Rotateq®</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/rotateq.jpg" border="0" alt="rotateq" title="rotateq" hspace="4" vspace="2" width="185" height="150" align="left" />Merck &amp; Co., Inc. today updated the prescribing information for ROTATEQ&reg; (rotavirus vaccine, live, oral pentavalent), the Company&#39;s vaccine to help prevent rotavirus gastroenteritis in infants and children. The labeling update includes post-marketing reports of intussusception and hematochezia to the Vaccine Adverse Events Reporting System (VAERS), a national vaccine safety surveillance program. </p><p>A naturally occurring event in infants, intussusception is estimated to occur in the U.S. in approximately 1 in 2,000 infants during the first year of life. Cases of intussusception can occur when no vaccine has been given and the cause is usually unknown. Today, the U.S. Food and Drug Administration (FDA) reported that since the licensure of ROTATEQ on Feb. 3, 2006 until Jan. 31, 2007, 28 cases of intussusception in infants who received ROTATEQ have been reported in the U.S. to VAERS and that this number does not exceed the number of cases expected based on the background rate. The FDA Public Health Notification on this label change is available at <a href="http://www.fda.gov/cber/safety/phnrota021307.htm" target="_blank">http://www.fda.gov/cber/safety/phnrota021307.htm</a>.</p>]]></description>
         <link>http://vaccine.immunodefence.com/2007/02/merck_updates_prescribing_info.html</link>
         <guid>http://vaccine.immunodefence.com/2007/02/merck_updates_prescribing_info.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Rotavirus Vaccine</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">merck</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">rotateq</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">rotavirus</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">safety</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccination for children</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">vaccine</category>
        
         <pubDate>Mon, 26 Feb 2007 16:38:49 +0100</pubDate>
      </item>
      
   </channel>
</rss>
